WO1997006769A2 - Composition pharmaceutique a proprietes trypanocides - Google Patents
Composition pharmaceutique a proprietes trypanocides Download PDFInfo
- Publication number
- WO1997006769A2 WO1997006769A2 PCT/EP1996/003657 EP9603657W WO9706769A2 WO 1997006769 A2 WO1997006769 A2 WO 1997006769A2 EP 9603657 W EP9603657 W EP 9603657W WO 9706769 A2 WO9706769 A2 WO 9706769A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical preparation
- preparation according
- water
- weight
- volume
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000654 trypanocidal effect Effects 0.000 title abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 22
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 claims abstract description 12
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000011187 glycerol Nutrition 0.000 claims abstract description 10
- 229960004448 pentamidine Drugs 0.000 claims abstract description 10
- 229960005222 phenazone Drugs 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 10
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 claims description 9
- 229950007095 diminazene Drugs 0.000 claims description 9
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 230000001754 anti-pyretic effect Effects 0.000 claims description 4
- 239000002221 antipyretic Substances 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- 239000003589 local anesthetic agent Substances 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000010411 cooking Methods 0.000 claims 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 229960005150 glycerol Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 9
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 229960002900 methylcellulose Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229950010741 aceturate Drugs 0.000 description 3
- 201000008680 babesiosis Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000223840 Babesia bigemina Species 0.000 description 1
- 241000223846 Babesia canis Species 0.000 description 1
- 241000675161 Babesia motasi Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000489254 Tetranychus takafujii Species 0.000 description 1
- 241000223778 Theileria annulata Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
Definitions
- the invention relates to a pharmaceutical preparation with trypanozid properties for the veterinary field, in the form of an aqueous solution, the diminazenediacetate (4,4'-diamidinodiazobenzenediacetamidoacetate) and pentamidine (4,4 '- (pentamethylendioxy) ) -dibenzamidine) as trypanozide active ingredients, phenazone (1,2-dihydro-l, 5-dimethyl-2-phenyl-3H-pyrazol-3-one) as antipyretic and analgesic component as well as glycerin.
- Arsenic preparations and trypan dyes are known as chemotherapeutic agents, but due to their arsenic
- a preparation for the treatment of such infections in animals is a trypanozide based on diminazen powder.
- Other commercially available trypanozides are also only available in powder form.
- the powdered form of the medicament is extremely disadvantageous, since the powdered preparations cannot be added to the feed and they therefore have to be mixed with water in order to prepare an injection solution. It is not possible to prepare a sterile solution from the powdery preparations, since the active substances crystallize out of the solution after a short time, so that the effectiveness of the preparation is quickly lost. Such solutions are therefore not adequately storable and transportable.
- the injection solution must therefore be prepared shortly before the injection, but this is very dangerous due to the generally available water, since it can generally contain bacteria, viruses and germs which cause additional infections in the animals, so that the animals are very heavily burdened by an additional infection.
- a complete solution of the solids is not achieved, so that the solution for injection has a poor effectiveness.
- the currently known powdery trypanozides thus represent a risk of additional infections or contamination, at the same time that There is a risk of underdosing of the therapeutic agent, so that the chemotherapy may have to be repeated, which naturally increases the risk potential for infections or the like.
- aqueous solutions of diminazene diacetate which contain castor oil as a solubilizer.
- the invention is therefore based on the object of providing a solution of a pharmaceutical preparation of the type mentioned at the outset which is stable even at high temperatures.
- the invention provides to create a pharmaceutical preparation with trypanozid properties in the form of an aqueous solution which contains the following substances: - Diminazene di-aceturate
- Diminazene diacetate and pentamidine are trypanoicidal active ingredients which have a different spectrum of activity and thus complement one another in their action, so that almost all types of blood parasites are detected. In addition, resistances are advantageously avoided by the combination.
- the poor water solubility of diminazene diacetate is compensated for by the combination of the two trypanozidic active substances according to the invention, since pentamidine, which is water soluble, acts as a solubilizer.
- the phenazone also brings about better solubility of the diminazene di-aceturate, in addition to its action as an analgesic, which advantageously alleviates pain and fever conditions in the animals which are caused by the injection or the infection.
- Glycerin and the water-soluble cellulose ether serve as emulsifiers.
- a stable aqueous solution can be obtained according to the combination of all of the aforementioned substances.
- the stability of the preparation according to the invention is advantageously so great that it can also be heated to 70 ° C. over a long period of time without any signs of decomposition occurring.
- Methyl-cellulose is preferably used as the water-soluble cellulose ether, although other cellulose ethers, such as, for. B. hydroxy-ethyl cellulose or hydroxypropyl cellulose or their mixed forms are suitable.
- the water used is preferably water which is physiologically, ie. H. in terms of pH and osmolality.
- the water is pH neutral and isotonic. It also has a saline content of 0.9 + 0.3%.
- aqueous solution is obtained as a preparation which can be stored without any problems since the active ingredient cannot crystallize out. In addition, there is no risk of an additional infection since it can be produced under sterile conditions.
- Babesiosis (Babesia bigemina, Babesia motasi, Babesia canis and other Babesia) Theileria annulata.
- the preparation according to the invention is combined with a further antipyretic substance and / or a pain reliever.
- a further antipyretic substance and / or a pain reliever.
- Lidocaine, procaine or their derivatives are preferably used. If necessary, acetylsalicylic acid can also be used as a fever and pain reliever.
- the preparation according to the invention contains isometadium hydrochloride from the group of the phenathridines as a further biocidal active ingredient.
- Methyl cellulose physiologically adjusted water 66.5 vol.-3
- composition in% by weight of the active ingredients is preferably:
- Methyl cellulose 1.6% physiologically adjusted water 78.4%.
- the preparation according to the invention has the advantage that, based on the volume, the active substance content can be doubled compared to the prior art.
- a particular advantage is that a single injection, which is necessary for chemotherapy, also provides three-month protection against reinfections.
- a preferred embodiment of the pharmaceutical preparation is produced by the biocidal active ingredients, the intended activity-reducing agents.
- water Emulsifier mixture can be mixed.
- the emulsifier / water mixture which is composed of glycerol 20% by volume, methyl cellulose 1.6% by volume and physiological water 78.4% by volume, is then added to the active substances.
- the ready-to-use preparation can be filled sterile filtered.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Cette composition pharmaceutique à propriétés trypanocides utile en médecine vétérinaire sous forme d'une solution aqueuse contient du diminazène-diacéturate, de la pentamidine, du phénazone, de la glycérine et un éther de cellulose soluble dans l'eau.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EA199800218A EA199800218A1 (ru) | 1995-08-21 | 1996-08-20 | Фармацевтический препарат с трипанозидными свойствами |
| APAP/P/1998/001196A AP827A (en) | 1995-08-21 | 1996-08-20 | Pharmaceutical preparation with trypanocidal qualities for veterinary use. |
| EP96929285A EP0845983A2 (fr) | 1995-08-21 | 1996-08-20 | Composition pharmaceutique a proprietes trypanocides |
| AU68750/96A AU6875096A (en) | 1995-08-21 | 1996-08-20 | Pharmaceutical composition with trypanocidal properties |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1995130708 DE19530708C2 (de) | 1995-08-21 | 1995-08-21 | Pharmazeutisches Präparat mit trypanoziden Eigenschaften |
| DE19530708.9 | 1995-08-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997006769A2 true WO1997006769A2 (fr) | 1997-02-27 |
| WO1997006769A3 WO1997006769A3 (fr) | 1997-05-09 |
Family
ID=7769997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/003657 WO1997006769A2 (fr) | 1995-08-21 | 1996-08-20 | Composition pharmaceutique a proprietes trypanocides |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0845983A2 (fr) |
| AP (1) | AP827A (fr) |
| AU (1) | AU6875096A (fr) |
| DE (1) | DE19530708C2 (fr) |
| EA (1) | EA199800218A1 (fr) |
| OA (1) | OA10665A (fr) |
| WO (1) | WO1997006769A2 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017266A3 (fr) * | 1996-10-18 | 1998-06-25 | Alain Jacques Bourdichon | Preparation pharmaceutique contenant un derive d'amidine et de la procaine |
| WO2000030611A3 (fr) * | 1998-11-24 | 2000-08-31 | Chambord Ltd | Preparation pharmaceutique |
| WO2004105772A1 (fr) * | 2003-06-03 | 2004-12-09 | Tropmed Gmbh | Preparation pharmaceutique destinee au traitement de maladies tropicales parasitaires contenant diminazene diaceturate et/ou pentamidine |
| CN105168121A (zh) * | 2015-08-28 | 2015-12-23 | 重庆布尔动物药业有限公司 | 兽用复方三氮脒注射液及其制备方法 |
| RU2638444C1 (ru) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Способ повышения лечебной эффективности пироплазмоза крупного рогатого скота Неозидином-М в сочетании с лазеропунктурой |
| RU2638433C1 (ru) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Способ повышения лечебной эффективности Диминазина-70 при пироплазмозе крупного рогатого скота |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4309415C2 (de) * | 1993-03-19 | 1996-11-07 | Alain Jaques Bourdichon | Pharmazeutisches Präparat |
-
1995
- 1995-08-21 DE DE1995130708 patent/DE19530708C2/de not_active Expired - Fee Related
-
1996
- 1996-08-20 AP APAP/P/1998/001196A patent/AP827A/en active
- 1996-08-20 AU AU68750/96A patent/AU6875096A/en not_active Abandoned
- 1996-08-20 WO PCT/EP1996/003657 patent/WO1997006769A2/fr not_active Application Discontinuation
- 1996-08-20 EP EP96929285A patent/EP0845983A2/fr not_active Ceased
- 1996-08-20 EA EA199800218A patent/EA199800218A1/ru unknown
-
1998
- 1998-02-20 OA OA9800022A patent/OA10665A/en unknown
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998017266A3 (fr) * | 1996-10-18 | 1998-06-25 | Alain Jacques Bourdichon | Preparation pharmaceutique contenant un derive d'amidine et de la procaine |
| WO2000030611A3 (fr) * | 1998-11-24 | 2000-08-31 | Chambord Ltd | Preparation pharmaceutique |
| WO2004105772A1 (fr) * | 2003-06-03 | 2004-12-09 | Tropmed Gmbh | Preparation pharmaceutique destinee au traitement de maladies tropicales parasitaires contenant diminazene diaceturate et/ou pentamidine |
| CN105168121A (zh) * | 2015-08-28 | 2015-12-23 | 重庆布尔动物药业有限公司 | 兽用复方三氮脒注射液及其制备方法 |
| RU2638444C1 (ru) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Способ повышения лечебной эффективности пироплазмоза крупного рогатого скота Неозидином-М в сочетании с лазеропунктурой |
| RU2638433C1 (ru) * | 2016-12-15 | 2017-12-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Горский государственный аграрный университет" | Способ повышения лечебной эффективности Диминазина-70 при пироплазмозе крупного рогатого скота |
Also Published As
| Publication number | Publication date |
|---|---|
| EA199800218A1 (ru) | 1998-12-24 |
| AP827A (en) | 2000-04-28 |
| AP9801196A0 (en) | 1998-03-31 |
| AU6875096A (en) | 1997-03-12 |
| EP0845983A2 (fr) | 1998-06-10 |
| DE19530708C2 (de) | 1999-01-07 |
| DE19530708A1 (de) | 1997-02-27 |
| WO1997006769A3 (fr) | 1997-05-09 |
| OA10665A (en) | 2002-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3612538C2 (fr) | ||
| DE19781981B3 (de) | Neue Pestizidkombination | |
| DE19782320B4 (de) | Insektizidkombination gegen Flöhe und Zecken von Säugern, insbesondere von Hunden und Katzen | |
| EP0117888B2 (fr) | Compositions liquides de dihydropyridines, leur préparation et application thérapeutique | |
| DE69818093T2 (de) | Langwirkende, injizierbare, formulierungen enthaltend rizinusöl | |
| DE60310377T2 (de) | Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung | |
| DE69923471T2 (de) | Injizierbare propofol-formulierungen | |
| EP0240829A2 (fr) | Agent carcinostatique | |
| DE69003906T2 (de) | Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen. | |
| DE69432982T2 (de) | Pour-on formulierung enthaltend polymerische material, glykole und glyzeriden | |
| DE60118132T2 (de) | Anthelmintika | |
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| EP0845983A2 (fr) | Composition pharmaceutique a proprietes trypanocides | |
| DE19780396B3 (de) | Direkt auf die Haut aufzubringende Lösung zur Parasitenbekämpfung bei Rindern und Schafen | |
| DE3619426A1 (de) | Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion | |
| EP1001756B1 (fr) | Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux | |
| EP2136816B1 (fr) | Oléyl-phosphocholine | |
| DE69910738T2 (de) | Fungizide zusammensetzung enthaltend ein n-benzoyl-n'-phenyl-harnstoff derivat | |
| DE60315597T2 (de) | Haloacetamidobenzoesäure derivate und deren verwendung zur behandlung von parasitären erkrankungen | |
| DE4309415C2 (de) | Pharmazeutisches Präparat | |
| DE202012013584U1 (de) | Pharmazeutische Formulierung enthaltend Curcumin | |
| EP1833499B1 (fr) | Agent homeopathique de prophylaxie contre des maladies causees par des parasites | |
| WO1996012504A1 (fr) | Formulation du type 'huile dans l'eau' pour application locale | |
| EP3275430A1 (fr) | Solution de curcumine pour infusion intraveineuse | |
| DE69524949T2 (de) | Eisen-Chelatierformulierung und Verfahren zu ihrer Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1996929285 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 199800218 Country of ref document: EA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1996929285 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1996929285 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1996929285 Country of ref document: EP |